Gaudium IVF and Women Health Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

Gaudium IVF and Women Health Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Gaudium IVF and Women Health shares trading at Rs.116 against a market capitalisation of Rs.852 Cr and a price-to-earnings multiple of Not meaningful. As a healthcare services name on the NSE and BSE, Gaudium IVF and Women Health enters the Gaudium IVF and Women Health Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

Quarterly financials for Gaudium IVF and Women Health are not yet fully available on Univest’s data partners for this cycle; investors should track Screener.in and the NSE/BSE filings directly for the Gaudium IVF and Women Health Q1 Results FY27 result date and cross-check any figures before making investment decisions.

Get Free Investment Predictions and Gaudium IVF and Women Health Research at Univest

Gaudium IVF and Women Health (NSE: GAUDIUMIVF) operates in the healthcare services space and is tracked on Univest under its NSE and BSE listings ahead of the Gaudium IVF and Women Health Q1 Results FY27 season, forming the base against which the Gaudium IVF and Women Health Q1 Results FY27 estimates in this article are built. This Gaudium IVF and Women Health Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Gaudium IVF and Women Health Q1 FY27 Estimates

Metric	Detail
CMP	Rs.116
Market Cap	Rs.852 Cr
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.117-132

Univest, a SEBI-Registered Investment Advisor, Tracks Gaudium IVF and Women Health Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. Occupancy and ARPOB Trends

Occupancy and ARPOB improvement across hospital and diagnostic networks is one of the primary variables that analysts are tracking ahead of Gaudium IVF and Women Health’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Gaudium IVF and Women Health share price target or faces renewed pressure.

2. Capacity Addition

Capacity addition through new beds or centres supporting medium-term growth is one of the primary variables that analysts are tracking ahead of Gaudium IVF and Women Health’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Gaudium IVF and Women Health share price target or faces renewed pressure.

3. Case Mix Improvement

Case mix improvement toward higher-margin specialties aiding profitability is one of the primary variables that analysts are tracking ahead of Gaudium IVF and Women Health’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Gaudium IVF and Women Health share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Gaudium IVF and Women Health’s live price and Q1 FY27 result updates.

Key Risks to the Gaudium IVF and Women Health Q1 Results FY27 Outlook

• Slower occupancy ramp-up in newly added capacity affecting near-term margins.
• Regulatory changes to pricing or insurance reimbursement norms.
• Talent cost inflation for specialist doctors and clinical staff.

Recent Performance Context

Detailed recent-quarter financials for Gaudium IVF and Women Health were not available from Univest’s data partners at the time of writing. Investors should check Screener.in or the company’s exchange filings for the latest verified numbers before the Q1 FY27 results.

Technical Analysis Ahead of Gaudium IVF and Women Health Q1 Results FY27

Gaudium IVF and Women Health shares last traded at Rs.116. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Gaudium IVF and Women Health Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Gaudium IVF and Women Health Q1 Results FY27 trailing-growth framework points to a range of Rs.114-123 for Gaudium IVF and Women Health, contingent on the Gaudium IVF and Women Health Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Gaudium IVF and Women Health Q1 Results FY27 view for Gaudium IVF and Women Health works out to Rs.117-132, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Gaudium IVF and Women Health Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Gaudium IVF and Women Health Q1 Results FY27 analysis would put Gaudium IVF and Women Health in a Rs.124-145 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Gaudium IVF and Women Health Q1 Results FY27 Print

• Revenue and PAT versus the Gaudium IVF and Women Health Q1 Results FY27 estimate range in this preview.
• Management commentary on FY27 growth guidance and margin trajectory relevant to the Gaudium IVF and Women Health Q1 Results FY27 narrative.
• Occupancy and ARPOB improvement across hospital and diagnostic networks
• Slower occupancy ramp-up in newly added capacity affecting near-term margins

Conclusion on Gaudium IVF and Women Health Q1 Results FY27

Gaudium IVF and Women Health enters the Q1 FY27 results season trading at Rs.116, with the 12-month Uniresearch target range of Rs.117-132 reflecting a tracking stance. Investors tracking the Gaudium IVF and Women Health Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

FAQs on Gaudium IVF and Women Health Q1 Results FY27

When are Gaudium IVF and Women Health Q1 FY27 results expected?

Ans. Gaudium IVF and Women Health’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Gaudium IVF and Women Health Q1 FY27 revenue estimate?

Ans. Detailed quarterly estimates are not available for Gaudium IVF and Women Health at this time; check Screener.in or the company’s exchange filings for verified numbers.

What is the Gaudium IVF and Women Health share price target?

Ans. The 12-month Uniresearch estimate for Gaudium IVF and Women Health share price target is Rs.117-132, based on trailing growth and current valuation multiples.

Is Gaudium IVF and Women Health a good buy before Q1 FY27 results?

Ans. Gaudium IVF and Women Health is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Gaudium IVF and Women Health’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and occupancy and ARPOB improvement across hospital and diagnostic networks.

Where can I track Gaudium IVF and Women Health share price live?

Ans. Gaudium IVF and Women Health share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.